Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Apr 02, 2013 12:22pm
269 Views
Post# 21198983

RE: RE: RE: RE: In for more

RE: RE: RE: RE: In for more

I invest based on catalysts and their impact on a company's fundamentals. So my answer to you is I have several identifiable catalysts that I will now be looking for, the timing of which is uncertain at this point. Once these catalysts occur I think it will be very easy for the company to have a much higher share price than today (I'm thinking 5x+ from the current price), but frankly I think it'll take some time for the catalysts to materialize (impossible to predict exact timing).

 

The exact path of the share price however is impossible to predict, even those technical analysts that have taken a run at HEM have only been correct about 50% of the time (flip a coin and you'll get the same results). Perhaps we see $2.00 in 6 months, perhaps 2 years, or perhaps we see $5.00+ in two years. In the meantime perhaps we see 50cents before we get there or perhaps the price goes back up to $1.00. IMO, these share price movements are just noise and not worth guessing. Am I surprised that the shares are back at 70 cents? Absolutely. Even absent key catalysts the fundamental value of the company is well north of $1.00, even as high as $2.00 IMO (assuming restructuring has no major hiccups). Accordingly I think $1.00 can happen at any time, even absent news releases. But who knows, maybe it'll still be a while before we get their or maybe not.

 

Longer term though, I can tell you I'm investing with confidence and that I think short term/impatient shareholders are going to really miss the boat. It also now makes sense to me why RH does not want to provide a forecast. If certain catalysts occur during 2013 then the outlook is vastly different than what it would be if those same catalysts occur in 2014. Lots of moving parts.

Bullboard Posts